Mammography for Ongoing Surveillance
For a stable heterogeneous, oval, circumscribed breast lesion, mammography should be used for ongoing surveillance in addition to ultrasound, not MRI.
Rationale
The imaging characteristics you describe—heterogeneous, oval, and circumscribed—suggest a probably benign lesion (BI-RADS 3). For such stable lesions in average-risk patients, the evidence strongly supports mammography as the appropriate surveillance modality.
Why Mammography is Preferred
- Standard of care for surveillance: Annual mammography remains the cornerstone of breast surveillance for most patients, with proven mortality reduction 1
- Cost-effectiveness: Mammography provides excellent diagnostic performance at reasonable cost without the expense and false-positive burden of MRI 2
- Appropriate sensitivity: For circumscribed masses with benign features, mammography combined with ultrasound provides adequate detection capability 3
When MRI Would Be Indicated Instead
MRI surveillance is not appropriate for your scenario unless the patient has specific high-risk features 1:
- Genetic predisposition (BRCA1/2 mutations or untested first-degree relatives)
- Lifetime breast cancer risk ≥20% based on validated risk models
- Personal history of breast cancer, especially if diagnosed before age 50-65 1
- Prior chest/mantle radiation before age 30 (begin MRI 8 years post-radiation but not before age 25)
- Lobular carcinoma in situ (LCIS) or atypical hyperplasia on prior biopsy 1
- Dense breast tissue combined with other risk factors 1
Surveillance Algorithm for Your Lesion
For a stable, probably benign lesion:
- Continue annual screening mammography (or digital breast tomosynthesis if available) 4, 5
- Targeted ultrasound at the site of the known lesion for direct comparison 6, 3
- Short-interval follow-up (6 months initially, then annually if stable) to document stability 3
- Return to routine screening after 2-3 years of documented stability
Critical Pitfall to Avoid
Do not order MRI for routine surveillance of benign-appearing lesions in average-risk patients. MRI has significantly higher false-positive rates (leading to unnecessary biopsies), substantially higher cost, and is not supported by guidelines for this indication 2. The high sensitivity of MRI (85-92%) comes at the expense of lower specificity, resulting in more anxiety and interventions without mortality benefit in average-risk populations 2.
The combination of mammography and targeted ultrasound provides optimal surveillance for your described lesion while minimizing false positives and healthcare costs.